TENX Stock Summary and Trading Ideas (Tenax Therapeutics | NASDAQ:TENX)

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

Tenax Therapeutics trades on the NASDAQ stock market under the symbol TENX.

As of August 19, 2026, TENX stock price climbed to $1.90 with 8,826,363 million shares trading.

TENX has a beta of 0.16, meaning it tends to be less sensitive to market movements. TENX has a correlation of 0.00 to the broad based SPY ETF.

TENX has a market cap of $50.40 million. This is considered a Micro Cap stock.

In the last 3 years, TENX traded as high as $61.20 and as low as $1.31.

The top ETF exchange traded funds that TENX belongs to (by Net Assets): VTI, VXF, VTWO, IWM, IWN.

TENX has underperformed the market in the last year with a price return of -68.4% while the SPY ETF gained +20.7%. TENX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -83.6% and -86.3%, respectively, while the SPY returned +4.4% and -0.3%, respectively.

TENX support price is $1.59 and resistance is $1.81 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TENX shares will trade within this expected range on the day.